DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c22hnd/inflammatory) has announced the addition of the "Inflammatory Bowel Disease Global Clinical Trials Review, H2, 2013" report to their offering.
This clinical trial report provides data on the inflammatory bowel disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on inflammatory bowel disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.
The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating the disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
-
Listings of discontinued trials (suspended, withdrawn and terminated)
Key Topics Covered:
List of Tables
List of Figures
Introduction
Inflammatory Bowel Disease
Report Guidance
Clinical Trials by Region
Clinical Trials by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Clinical Trials by BRIC Nations
In Progress Trials by Phase
Clinical Trials by Trial Status
Unaccomplished Trials of Inflammatory Bowel Disease
Subjects Recruited Over a Period of Time
Prominent Sponsors
Top Companies Participating in Inflammatory Bowel Disease Therapeutics Clinical Trials
Prominent Drug Comparison
Clinical Trial Profiles
Clinical Trial Overview of Top Companies
Five Key Clinical Profiles
Appendix
Companies Mentioned:
- AbbVie Inc.
- Alba Therapeutics Corporation
- Alvine Pharmaceuticals, Inc.
- Amgen Inc.
- AstraZeneca PLC
- Ferring Pharmaceuticals, Inc.
- Genzyme Corporation
- Given Imaging Ltd.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Pfizer Inc.
- UCB S.A.
For more information visit http://www.researchandmarkets.com/research/c22hnd/inflammatory
